Ricks, chair and CEO of Eli Lilly, current utilization of GLP-1s remains low relative to the population that could benefit, citing fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn't serious enough for treatment. 2 We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications, Ricks said
The Lancet Diabetes & Endocrinology , 12(2), 89-101
A study of the nucleation and growth processes in the synthesis of colloidal gold
Se enzyme and the whole thioredoxin system are directly reduce the content of lipid peroxide, protect vascular endothelial cells from oxidative damage, and inhibit Low Density Lipoprotein (LDL) oxidation (Furman et al., 2004